Inogen (NASDAQ:INGN) Upgraded at StockNews.com

StockNews.com upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a report issued on Tuesday.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Friday, November 8th.

Inogen Stock Performance

NASDAQ:INGN traded down $0.13 during mid-day trading on Tuesday, hitting $9.82. The company had a trading volume of 31,840 shares, compared to its average volume of 332,986. Inogen has a fifty-two week low of $4.93 and a fifty-two week high of $13.33. The firm has a market cap of $233.91 million, a P/E ratio of -4.42 and a beta of 1.04. The business’s fifty day moving average is $9.88 and its two-hundred day moving average is $9.49.

Institutional Trading of Inogen

Institutional investors have recently modified their holdings of the company. Divisadero Street Capital Management LP raised its position in Inogen by 682.3% in the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after buying an additional 2,046,766 shares during the last quarter. Brown Capital Management LLC raised its holdings in shares of Inogen by 26.6% in the first quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock valued at $15,941,000 after purchasing an additional 414,903 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Inogen by 4.9% in the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock worth $11,492,000 after purchasing an additional 65,954 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Inogen by 29.3% in the second quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after purchasing an additional 129,307 shares in the last quarter. Finally, Meros Investment Management LP boosted its holdings in Inogen by 1.6% during the second quarter. Meros Investment Management LP now owns 397,209 shares of the medical technology company’s stock worth $3,229,000 after purchasing an additional 6,385 shares during the last quarter. 89.94% of the stock is currently owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.